Tirzepatide, the active pharmaceutical ingredient for Mounjaro and Zepbound, increased in popularity by 373% in one year. These four medications are all glucagon-like peptide-1 receptor agonists; and Zepbound is also a glucose-dependent insulinotropic polypeptide.
GLP-1s, which are approved for Type 2 diabetes, weight loss and cardiovascular problems, are part of a booming industry. The manufacturer of Ozempic and Mounjaro, Novo Nordisk, recently became and has remained Europe’s most valuable public company.
The research calculated healthcare drug expenditure among three factors: a drug’s list price, newly approved drugs and utilization.
The top 25 drugs ranked by U.S. expenditure in 2023, according to the study:
1. Semaglutide — $38.6 billion (100.1% change from 2022)
2. Adalimumab — $35.3 billion (9.1% change)
3. Apixaban — $22.1 billion (17.1% change)
4. Dulaglutide — $16.3 billion (5.1% change)
5. Empagliflozin — $15.9 billion (34% change)
6. Ustekinumab — $15.9 billion (14% change)
7. Pembrolizumab — $15.4 billion (19.1% change)
8. Tirzepatide — $13.2 billion (373.1% change)
9. Bictegravir/emtricitabine/tenofovir alafenamide — $13.2 billion (14.2% change)
10. Dupilumab — $11.5 billion (44.9% change)
11. Risankizumab — $10.1 billion (106.3% change)
12. Etanercept — $9.5 billion (6.9% change)
13. Insulin glargine — $8.9 billion (-4.6% change)
14. Rivaroxaban — $8.3 billion (1.9% change)
15. Dapagliflozin — $7.9 billion (41.8% change)
16. Immune globulin — $6.3 billion (2.5% change)
17. Insulin aspart — $5.8 billion (-3.5% change)
18. Secukinumab — $5.7 billion (8.6% change)
19. Sitagliptin — $5.7 billion (-9.4% change)
20. Fluticasone/umeclidinium bromide/vilanterol — $5.7 billion (28.8% change)
21. Nivolumab — $5.4 billion (9.8% change)
22. Lisdexamfetamine — $5.4 billion (15% change)
23. Insulin lispro — $5.3 billion (-1.8% change)
24. Ixekizumab — $5.3 billion (16.1% change)
25. Ocrelizumab — $5.3 billion (11% change)
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.